E. M. Golovina

E. M. Golovina

Auto-generated profile, based on publicly available information

E. M. Golovina

Regional Children’s Clinical Hospital

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
EGE. M. Golovina
E. M. Golovina
APA. V. Poletaev
A. V. Poletaev
ESE. A. Seregina
E. A. Seregina
DFD. V. Fedorova
D. V. Fedorova
APA. V. Pshonkin
A. V. Pshonkin
PZP. A. Zharkov
P. A. Zharkov
Even though von Willebrand disease (vWD) is a common bleeding disorder, it comprises some rare types as well. Type 2B vWD is usually diagnosed in 3-5% of all vWD cases. The important diagnostic markers of this disease subtype include thrombocytopenia, decreased von Willebrand factor (vWF) activity, increased low-dose ristocetin-induced platelet aggregation, and identification of mutations in exon 28 of the vWF gene. The purpose of this study was to highlight challenges associated with the differential diagnosis of vWD as well as to demonstrate heterogeneous clinical and laboratory signs of type 2B vWD. Here, we retrospectively analyzed all the cases of type 2B vWD diagnosed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. For the analysis, we used de-identified data collected during routine clinical care and hence did not need an approval from the Local Ethics Committee. All the patients had undergone medical history assessment and laboratory investigations and had been evaluated for bleeding disorders using the Pediatric Bleeding Questionnaire. Type 2B vWD was diagnosed based on the following criteria: bleeding symptoms, thrombocytopenia, significantly decreased vWF ristocetin-cofactor activity, normal or decreased vWF antigen levels, ristocetin-cofactor activity/vWF antigen ratio 0.7; increased low-dose ristocetin-induced platelet aggregation. Type 2B vWD was diagnosed in 7 patients. Out of these, 5 had bleeding symptoms and 2 had a family history of vWD. All the children had been diagnosed with thrombocytopenia during their first year of life. Five patients had been initially diagnosed with immune thrombocytopenia, with one girl having a family history of vWD. All the patients with diagnosed immune thrombocytopenia had been treated with intravenous immunoglobulins, and one child had also undergone treatment with corticosteroids. Three patients had had to be admitted to hospital for major bleeding before they were diagnosed with vWD. All the patients had the typical laboratory phenotype, and five out of them demonstrated decreased vWF collagen-binding activity. In two patients with positive family history, the diagnosis was genetically verified, with both of them harboring mutations in exons 20 and 28 of the vWF gene. Our findings are consistent with the literature suggesting how challenging differential diagnosis of this vWD type is. Still, a low-dose ristocetin-induced platelet aggregation test along with other laboratory investigations can be used to effectively identify the type 2B vWD phenotype. In Russia, factor replacement therapy remains the primary treatment option for patients with any type of vWD.

25 October 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
EGE.M. Golovina
E.M. Golovina
RHRostov-On-Don Rostov Oblast Regional Children'S Clinical Hospital
Rostov-On-Don Rostov Oblast Regional Children'S Clinical Hospital
KAK.S. Aslanyan
K.S. Aslanyan
ATAlexander Tushev
Alexander Tushev
PZP.A. Zharkov
P.A. Zharkov
Late-onset Vitamin K deficiency bleeding is a rare disease that develops as a manifestation of Vitamin K deficiency in children from 8 days to 6 months of age with an incidence of 4.4 to 72 cases per 100,000 newborns in countries where prophylaxis with Vitamin K1 preparations is not carried out and of 0 to 3 cases per 100,000 in countries where prophylaxis is carried out. In Russia the prophylaxis is carried out using menadione sodium bisulfite, a Vitamin K3 preparation, the effectiveness of which is questionable. One of the specific manifestations of the late-onset Vitamin K deficiency bleeding is intracranial hemorrhage (ICH), which occurs in more than half of all cases of the disease. This disease has not been described in patients with hemophilia A until now. Authors represent a clinical case report of the development of the late-onset Vitamin K deficiency bleeding by a massive ICH in a patient with hemophilia A.

13 December 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
EGE. M. Golovina
E. M. Golovina
КAК. S. Aslanyan
К. S. Aslanyan
Vitamin K-dependent coagulopathy caused by vitamin K deficiency holds an important place among bleeding disorders in newborns and infants. The late type of this disease is considered to be the most dangerous one because up to 50% of children develop intracranial hemorrhage which often leads to disability or even death if diagnosis is delayed. Here, we report on the prevalence, treatment and prevention of vitamin K-dependent coagulopathy in neonates and infants.

12 August 2024 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
EGE. M. Golovina
E. M. Golovina
KAK. S. Aslanyan
K. S. Aslanyan
PZP. A. Zharkov
P. A. Zharkov
Relevance. Late-onset vitamin K deficiency bleeding is considered a successfully preventable condition, however, current data on morbidity in the group of children who received prophylactic administration of menadion are missing, and the effectiveness of the drug is questionable. At the same time, late diagnosis of this disease often leads to disability and death of patients.The purpose of the study – to demonstrate the high prevalence of late vitamin K-dependent coagulopathy in a group of healthy full-term infants who received prophylactic administration of menadione sodium bisulfite.Materials and methods. The retrospective analysis included all children who had an established diagnosis of late-onset vitamin K deficiency bleeding and were treated at the Rostov Regional Children’s Clinical Hospital. All patients underwent an assessment of their medical history and necessary laboratory examinations. The diagnosis was made on the basis of the following criteria: spontaneous bleeding occurring between day 8 and month 6 of life; and characteristic changes in the coagulation parameters, with no evidence of hereditary coagulopathies.Results. The diagnosis of late-onset vitamin K deficiency bleeding was established in 13 children. 11 of them received prophylactic menadione administration in the hospital. Out of the 8 full-term healthy children who received the prophylaxis, 3 developed spontaneous intracranial hemorrhages and one patient died. In all cases, after the administration of menadione, coagulation parameters returned to normal.Conclusion. Prophylactic administration of menadione is probably not effective enough in preventing late-onset Vitamin K deficiency bleeding. Further research into the effectiveness of this medication may allow us to revise the current recommendations and lower the incidence of this condition.